Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients

• Status: Not yet recruiting
• Trial end date: 2024-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more. However, even after chemoradiation, the 5-year distant-metastasis rate of patients with N2-3 NPC is still 36.7%. Aspirin is proven in lab and clinical studies to have the abilities of inhibiting the inflammation which could enhance metastasis of breast and colorectal cancers. And before this study, it was discovered that regular aspirin intake might be associated with distant-metastasis-free survival (MFS) and OS independently. So this Phase 2 trial was conducted to validate the impact of aspirin on prognosis of N2-3 NPC.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Pathologic dianosis of nasopharyngeal carcinoma

• Stage of T1-4N2-3M0 (UICC/AJCC classification ver. 7)

• 18-70 years old

• Karnofsky performance score > 70

Exclusion Criteria:

• Distant metastasis before or during radiotherapy

• Severe dysfunctions of liver, kidney, lung, heart of bone marrow which are not fit for radiotherapy

• Prior malignancies

• Prior history of radiotherapy, chemotherapy or monoclonal antibody therapy

• Participation of other drug trials within 3 months

• Regular use of aspirin before dianosis

• Contraindication or allergy of aspirin

• Patients who are considered by the researchers not suitable to participate this trial